New clinical trials targeting the LRRK2 gene

LRRK2 is a protein that becomes hyperactive in some people with Parkinson’s, and this increased level of activity is believed to be involved in the progression of their Parkinson’s. Now, two biotech companies have announced plans for two new clinical trials to test their ‘LRRK2…

News Research news

Tackling toxic alpha-synuclein

Three major lines of clinical investigation are currently underway to determine if stopping the clustering of alpha-synuclein in Parkinson’s can help to slow down the progression of the disease.

The Anle138b Trial

This clinical trial is testing a small molecule called Anle138b to assess its potential to inhibit alpha-synuclein masses accumulating. In Parkinson’s, alpha-synuclein, which is abundant in nerve cells, begins clumping together (or aggregating) and it is believed that this process could be toxic. This trial, it is hoped, will slow-down…

PD Frontline

As research has expanded in the area of Parkinson’s genetics, researchers have been able to uncover a number of genes which have been linked to an increased risk of developing Parkinson’s. About 20% of Parkinson’s diagnoses are associated with genetic variations. Researchers believe that by…

The PROSEEK trial – vodobatinib

Sun Pharma Advanced Research Company (SPARC) is conducting a Phase ll clinical trial to evaluate the safety and effectiveness of its experimental c-Abl inhibitor vodobatinib (previously known as KO706) in people with early Parkinson’s.